CoChat

Anti-Acid Drug Treatment Induces Changes in the Gut Microbiome Composition of Hemodialysis Patients

Open access

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Anti-acid drugs, proton pump inhibitor (PPI) and histamine-2 blocker (H2-blocker), are commonly prescribed to treat gastrointestinal disorders. These anti-acid drugs alter gut microbiota in the general population, but their effects are not known in hemodialysis patients. Hence, we investigated the microbiota composition in hemodialysis patients treated with PPIs or H2-blocker. Among 193 hemodialysis patients, we identified 32 H2-blocker users, 23 PPI users, and 138 no anti-acid drug subjects. Fecal samples were obtained to analyze the gut microbiome using 16S RNA amplicon sequencing. Differences in the microbial composition of the H2-blocker users, PPI users, and controls were assessed using linear discriminant analysis effect size and the random forest algorithm. The species richness or evenness (α-diversity) was similar among the three groups, whereas the inter-individual diversity (β-diversity) was different between H2-blocker users, PPI users, and controls. Hemodialysis patients treated with H2-blocker and PPIs had a higher microbial dysbiosis index than the controls, with a significant increase in the genera Provetella 2, Phascolarctobacterium, Christensenellaceae R-7 group, and Eubacterium oxidoreducens group in H2-blocker users, and Streptococcus and Veillonella in PPI users. In addition, compared to the H2-blocker users, there was a significant enrichment of the genera Streptococcus in PPI users, as confirmed by the random forest analysis and the confounder-adjusted regression model. In conclusion, PPIs significantly changed the gut microbiota composition in hemodialysis patients compared to H2-blocker users or controls. Importantly, the Streptococcus genus was significantly increased in PPI treatment. These findings caution against the overuse of PPIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/microorganisms9020286

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The α-diversity and microbial dysbiosis index in hemodialysis patients with proton pump inhibitor (PPI) users, H2-blocker users, and controls: (A) no difference in richness (Chao 1 index) or evenness (Shannon index, Simpson index, Inverse Simpson index); (B) proton pump inhibitor users or H2-blocker users had a higher microbial dysbiosis index compared to the controls.
Figure 1 The α-diversity and microbial dysbiosis index in hemodialysis patients with proton pump inhibitor (PPI) users, H2-blocker users, and controls: (A) no difference in richness (Chao 1 index) or evenness (Shannon index, Simpson index, Inverse Simpson index); (B) proton pump inhibitor users or H2-blocker users had a higher microbial dysbiosis index compared to the controls.CC BY · PubMed Central
Figure 2 The β-diversity in hemodialysis patients with proton pump inhibitor users, H2-blocker users, and controls (Bray–Curtis index, Jensen–Shannon divergence, and Jaccard index). Differences in β-diversity were tested by permutational multivariate analysis of variance using distance matrices (PERMANOVA).
Figure 2 The β-diversity in hemodialysis patients with proton pump inhibitor users, H2-blocker users, and controls (Bray–Curtis index, Jensen–Shannon divergence, and Jaccard index). Differences in β-diversity were tested by permutational multivariate analysis of variance using distance matrices (PERMANOVA).CC BY · PubMed Central
Figure 3 Linear discriminative analysis (LDA) effect size (LEfSe) analysis between H2-blocker users (blue), proton pump inhibitor users (green) and controls (red) at the (A) genus level and (B) family level.
Figure 3 Linear discriminative analysis (LDA) effect size (LEfSe) analysis between H2-blocker users (blue), proton pump inhibitor users (green) and controls (red) at the (A) genus level and (B) family level.CC BY · PubMed Central
Figure 4 Heat tree visualization of taxonomic differences. A heat tree illustrates the taxonomic differences between H2-blocker users, proton pump inhibitor users, and controls. The color gradient and the size of the node, edge, and label are based on the log2 ratio of median abundance: (A) controls versus H2-blocker users; (B) controls versus proton pump inhibitor users; (C) H2-blocker users versus proton pump inhibitor users.
Figure 4 Heat tree visualization of taxonomic differences. A heat tree illustrates the taxonomic differences between H2-blocker users, proton pump inhibitor users, and controls. The color gradient and the size of the node, edge, and label are based on the log2 ratio of median abundance: (A) controls versus H2-blocker users; (B) controls versus proton pump inhibitor users; (C) H2-blocker users versus proton pump inhibitor users.CC BY · PubMed Central
Figure 5 Determination of bacteria-specificity for discrimination across H2-blocker users, proton pump inhibitor users, and controls in hemodialysis patients. The anti-acid drugs discriminatory taxa were determined by applying random forest analysis using the (A) species-levels abundance; (B) genus-level abundance; and (C) family-level abundance.
Figure 5 Determination of bacteria-specificity for discrimination across H2-blocker users, proton pump inhibitor users, and controls in hemodialysis patients. The anti-acid drugs discriminatory taxa were determined by applying random forest analysis using the (A) species-levels abundance; (B) genus-level abundance; and (C) family-level abundance.CC BY · PubMed Central
Figure 6 Taxonomic differences were detected between the proton pump inhibitor users and H2-blocker users: (A) cladogram showing differentially abundant taxonomic clades with an LDA score > 4.0 among PPI users and H2-blocker users; (B) linear discriminative analysis (LDA) effect size (LEfSe) analysis between proton pump inhibitor users (green) and H2-blocker users (red).
Figure 6 Taxonomic differences were detected between the proton pump inhibitor users and H2-blocker users: (A) cladogram showing differentially abundant taxonomic clades with an LDA score > 4.0 among PPI users and H2-blocker users; (B) linear discriminative analysis (LDA) effect size (LEfSe) analysis between proton pump inhibitor users (green) and H2-blocker users (red).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

Metadata

Authors
Lin, Y.-T., Lin, T.-Y., Hung, S.-C., Liu, P.-Y., Wu, P.-H., Chuang, Y.-S., Hung, W.-C., Chiu, Y.-W., Kuo, M.-C., & Wu, C.-Y.
Affiliations
  • Kaohsiung Medical University (TW)
  • Tzu Chi University (TW)
  • National Taiwan University (TW)
  • Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
  • National Health Research Institutes (TW)
Corresponding author
Wu, Ping-Hsun
Venue
Microorganisms
Publisher
MDPI AG
Published
2021-01-30
Volume
9
Issue
2
Pages
286
ISSN
2076-2607 (ISSN-L)
OpenAlex
W3129141123
Cited by
22
References
49
Citations by year
2026: 4 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 1 · 2021: 2
FWCI
1.18
Type
journal article
Language
en
Open access
Locations
  • Microorganisms (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministry of Science and Technology, Taiwan (MOST 106-2314-B-037-054, MOST 107-2314-B-037-104, and MOST 107-2314-B-037-098-MY3)
  • Kaohsiung Medical University Hospital, Taiwan (KMUH105-5R15, KMUH106-6R17, KMUH106-6T03, KMUH107-7R16, KMUH107-7R78, KMUH108-8M11, and KMUH108-8R70)
  • Kaohsiung Medical University, Taiwan (KMU-Q108024 and KMU-Q108027)
  • NSYSU-KMU JOINT RESEARCH PROJECT (NSYSUKMU 105-I005 and NSYSUKMU 106-I005)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
proton pump inhibitors, H2 receptor antagonists, gut microbiota, hemodialysis patients, dysbiosis, Streptococcus, Phascolarctobacterium, Christensenellaceae, Veillonella, beta diversity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.